Cargando…

Development of transgenic Caenorhabditis elegans expressing human transthyretin as a model for drug screening

Familial amyloid polyneuropathy is a hereditary systemic amyloidosis caused by a mutation in the transthyretin (TTR) gene. Amyloid deposits in tissues of patients contain not only full-length TTR but also C-terminal TTR fragments. However, in vivo models to evaluate the pathogenicity of TTR fragment...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsuda, Yukimoto, Yamanaka, Kunitoshi, Toyoshima, Risa, Ueda, Mitsuharu, Masuda, Teruaki, Misumi, Yohei, Ogura, Teru, Ando, Yukio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6294829/
https://www.ncbi.nlm.nih.gov/pubmed/30552363
http://dx.doi.org/10.1038/s41598-018-36357-5
_version_ 1783380795941978112
author Tsuda, Yukimoto
Yamanaka, Kunitoshi
Toyoshima, Risa
Ueda, Mitsuharu
Masuda, Teruaki
Misumi, Yohei
Ogura, Teru
Ando, Yukio
author_facet Tsuda, Yukimoto
Yamanaka, Kunitoshi
Toyoshima, Risa
Ueda, Mitsuharu
Masuda, Teruaki
Misumi, Yohei
Ogura, Teru
Ando, Yukio
author_sort Tsuda, Yukimoto
collection PubMed
description Familial amyloid polyneuropathy is a hereditary systemic amyloidosis caused by a mutation in the transthyretin (TTR) gene. Amyloid deposits in tissues of patients contain not only full-length TTR but also C-terminal TTR fragments. However, in vivo models to evaluate the pathogenicity of TTR fragments have not yet been developed. Here, we generated transgenic Caenorhabditis elegans strains expressing several types of TTR fragments or full-length TTR fused to enhanced green fluorescent protein in the body wall muscle cells and analyzed the phenotypes of the worms. The transgenic strain expressing residues 81–127 of TTR, which included the β-strands F and H, formed aggregates and caused defective worm motility and a significantly shortened lifespan compared with other strains. These findings suggest that the C-terminal fragments of TTR may contribute to cytotoxicity of TTR amyloidosis in vivo. By using this C. elegans model system, we found that (−)-epigallocatechin-3-gallate, a major polyphenol in green tea, significantly inhibited the formation of aggregates, the defective motility, and the shortened lifespan caused by residues 81–127 of TTR. These results suggest that our newly developed C. elegans model system will be useful for in vivo pathological analyses of TTR amyloidosis as well as drug screening.
format Online
Article
Text
id pubmed-6294829
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-62948292018-12-24 Development of transgenic Caenorhabditis elegans expressing human transthyretin as a model for drug screening Tsuda, Yukimoto Yamanaka, Kunitoshi Toyoshima, Risa Ueda, Mitsuharu Masuda, Teruaki Misumi, Yohei Ogura, Teru Ando, Yukio Sci Rep Article Familial amyloid polyneuropathy is a hereditary systemic amyloidosis caused by a mutation in the transthyretin (TTR) gene. Amyloid deposits in tissues of patients contain not only full-length TTR but also C-terminal TTR fragments. However, in vivo models to evaluate the pathogenicity of TTR fragments have not yet been developed. Here, we generated transgenic Caenorhabditis elegans strains expressing several types of TTR fragments or full-length TTR fused to enhanced green fluorescent protein in the body wall muscle cells and analyzed the phenotypes of the worms. The transgenic strain expressing residues 81–127 of TTR, which included the β-strands F and H, formed aggregates and caused defective worm motility and a significantly shortened lifespan compared with other strains. These findings suggest that the C-terminal fragments of TTR may contribute to cytotoxicity of TTR amyloidosis in vivo. By using this C. elegans model system, we found that (−)-epigallocatechin-3-gallate, a major polyphenol in green tea, significantly inhibited the formation of aggregates, the defective motility, and the shortened lifespan caused by residues 81–127 of TTR. These results suggest that our newly developed C. elegans model system will be useful for in vivo pathological analyses of TTR amyloidosis as well as drug screening. Nature Publishing Group UK 2018-12-14 /pmc/articles/PMC6294829/ /pubmed/30552363 http://dx.doi.org/10.1038/s41598-018-36357-5 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Tsuda, Yukimoto
Yamanaka, Kunitoshi
Toyoshima, Risa
Ueda, Mitsuharu
Masuda, Teruaki
Misumi, Yohei
Ogura, Teru
Ando, Yukio
Development of transgenic Caenorhabditis elegans expressing human transthyretin as a model for drug screening
title Development of transgenic Caenorhabditis elegans expressing human transthyretin as a model for drug screening
title_full Development of transgenic Caenorhabditis elegans expressing human transthyretin as a model for drug screening
title_fullStr Development of transgenic Caenorhabditis elegans expressing human transthyretin as a model for drug screening
title_full_unstemmed Development of transgenic Caenorhabditis elegans expressing human transthyretin as a model for drug screening
title_short Development of transgenic Caenorhabditis elegans expressing human transthyretin as a model for drug screening
title_sort development of transgenic caenorhabditis elegans expressing human transthyretin as a model for drug screening
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6294829/
https://www.ncbi.nlm.nih.gov/pubmed/30552363
http://dx.doi.org/10.1038/s41598-018-36357-5
work_keys_str_mv AT tsudayukimoto developmentoftransgeniccaenorhabditiselegansexpressinghumantransthyretinasamodelfordrugscreening
AT yamanakakunitoshi developmentoftransgeniccaenorhabditiselegansexpressinghumantransthyretinasamodelfordrugscreening
AT toyoshimarisa developmentoftransgeniccaenorhabditiselegansexpressinghumantransthyretinasamodelfordrugscreening
AT uedamitsuharu developmentoftransgeniccaenorhabditiselegansexpressinghumantransthyretinasamodelfordrugscreening
AT masudateruaki developmentoftransgeniccaenorhabditiselegansexpressinghumantransthyretinasamodelfordrugscreening
AT misumiyohei developmentoftransgeniccaenorhabditiselegansexpressinghumantransthyretinasamodelfordrugscreening
AT ogurateru developmentoftransgeniccaenorhabditiselegansexpressinghumantransthyretinasamodelfordrugscreening
AT andoyukio developmentoftransgeniccaenorhabditiselegansexpressinghumantransthyretinasamodelfordrugscreening